Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Pharmacogenetic Predictors of Cannabidiol Response and Tolerability in Treatment-Resistant Epilepsy.

Clinical pharmacology and therapeutics - 1 Nov 2021

Davis Brittney H, Beasley T Mark, Amaral Michelle, Szaflarski Jerzy P, Gaston Tyler, Perry Grayson Leslie, Standaert David G, Bebin E Martina, Limdi Nita A

Abstract excerpt

In patients with treatment-resistant epilepsy (TRE), cannabidiol (CBD) produces variable improvement in seizure control. Patients in the University of Alabama at Birmingham CBD Expanded Access Program (EAP) were enrolled in the genomic study and genotyped using the Affymetrix Drug Metabolizing Enzymes and Transporters plus array. Associations between variants and CBD response (≥50% seizure reduction) and...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Anticonvulsants
Share to Child, Preschool

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Diarrhea

Share to Drug Resistant Epilepsy

Share to Forecasting

Share to Gene Regulatory Networks

Share to Pharmacogenetics

Share to Treatment Outcome

Source

Open in PubMed Open full text

Identifiers

PMID: 34464454
DOI: 10.1002/cpt.2408
PMCID: PMC8530979

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Pharmacogenetic Predictors of Cannabidiol Response and Tolerability in Treatment-Resistant Epilepsy.PMID 34464454Read ↗

The association of ABCB1 gene polymorphism with clinical response to carbamazepine monotherapy in patients with epilepsy.Semantic proximity Read ↗

Association of xenobiotic receptor polymorphisms with carbamazepine response in epilepsy patients.Semantic proximity Read ↗

Pharmacogenetics of CannabinoidsSemantic proximity Read ↗

Genetics and Antiepileptic Mood Stabilizer Treatment Response in Bipolar Disorder: What do we Know?Semantic proximity Read ↗

Pharmaceutical Repurposing Strategies for Metabolic Disorders: Insights from Mendelian Randomization StudiesSemantic proximity Read ↗

Association of ABCB1 polymorphisms with carbamazepine metabolism and resistance in epilepsy: A meta-analysis.Semantic proximity Read ↗

Association study of 27 annotated genes for clozapine pharmacogenetics: validation of preexisting studies and identification of a new candidate gene, ABCB1, for treatment response.Semantic proximity Read ↗

Association of intestinal anti-inflammatory drug target genes with psychiatric Disorders: A Mendelian randomization study.Semantic proximity Read ↗

Genome-wide association study: Exploring the genetic basis for responsiveness to ketogenic dietary therapies for drug-resistant epilepsy.Semantic proximity Read ↗

Epilepsy PharmacogeneticsSemantic proximity Read ↗

Pharmacogenetics of Carbamazepine: A Systematic Review on CYP3A4 and CYP3A5 Polymorphisms.Semantic proximity Read ↗

Pharmacogenomic association study on the role of drug metabolizing, drug transporters and drug target gene polymorphisms in drug-resistant epilepsy in a north Indian populationSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.